Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Early survival prediction in non-small cell lung cancer from PET/CT images using an intra-tumor partitioning method.

Astaraki M, Wang C, Buizza G, Toma-Dasu I, Lazzeroni M, Smedby Ö.

Phys Med. 2019 Apr;60:58-65. doi: 10.1016/j.ejmp.2019.03.024. Epub 2019 Mar 27.

PMID:
31000087
2.

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.

DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Taverniti C, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Branchi D, Campora S, Petrera M, Buttiron Webber T, Boni L, Bonanni B.

J Clin Oncol. 2019 Jul 1;37(19):1629-1637. doi: 10.1200/JCO.18.01779. Epub 2019 Apr 11.

3.

Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.

Johansson H, Aristarco V, Gandini S, Gjerde J, Macis D, Guerrieri-Gonzaga A, Serrano D, Lazzeroni M, Rajasekaran A, Williard CV, Mellgren G, DeCensi A, Bonanni B.

Pharmacogenomics J. 2019 Apr 10. doi: 10.1038/s41397-019-0087-z. [Epub ahead of print]

PMID:
30967597
4.

Impact of Tumour Cell Infiltration on Treatment Outcome in Gamma Knife Radiosurgery: A Modelling Study.

Lazzeroni M, Manesh ZK, Sandström H, Barsoum P, Toma-Dasu I.

Anticancer Res. 2019 Apr;39(4):1675-1687. doi: 10.21873/anticanres.13273.

PMID:
30952706
5.

Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series.

Leonardi MC, Corrao G, Frassoni S, Vingiani A, Dicuonzo S, Lazzeroni M, Fodor C, Morra A, Gerardi MA, Rojas DP, Dell'Acqua V, Marvaso G, Bassi FD, Galimberti VE, Veronesi P, Miglietta E, Cattani F, Zurrida S, Bagnardi V, Viale G, Orecchia R, Jereczek-Fossa BA.

Radiother Oncol. 2019 Apr;133:68-76. doi: 10.1016/j.radonc.2018.12.030. Epub 2019 Jan 17.

PMID:
30935584
6.

The risk of extra-ovarian malignancies among women with endometriosis: A systematic literature review and meta-analysis.

Gandini S, Lazzeroni M, Peccatori FA, Bendinelli B, Saieva C, Palli D, Masala G, Caini S.

Crit Rev Oncol Hematol. 2019 Feb;134:72-81. doi: 10.1016/j.critrevonc.2018.12.009. Epub 2019 Jan 9.

PMID:
30771877
7.

Hibernation in bats (Mammalia: Chiroptera) did not evolve through positive selection of leptin.

Lazzeroni ME, Burbrink FT, Simmons NB.

Ecol Evol. 2018 Nov 28;8(24):12576-12596. doi: 10.1002/ece3.4674. eCollection 2018 Dec.

8.

Early tumor response prediction for lung cancer patients using novel longitudinal pattern features from sequential PET/CT image scans.

Buizza G, Toma-Dasu I, Lazzeroni M, Paganelli C, Riboldi M, Chang Y, Smedby Ö, Wang C.

Phys Med. 2018 Oct;54:21-29. doi: 10.1016/j.ejmp.2018.09.003. Epub 2018 Sep 22.

PMID:
30337006
9.

Mathematical Description of Changes in Tumour Oxygenation from Repeated Functional Imaging.

Lazzeroni M, Bunea H, Grosu AL, Baltas D, Toma-Dasu I, Dasu A.

Adv Exp Med Biol. 2018;1072:195-200. doi: 10.1007/978-3-319-91287-5_31.

PMID:
30178345
10.

Evaluation of third treatment week as temporal window for assessing responsiveness on repeated FDG-PET-CT scans in Non-Small Cell Lung Cancer patients.

Lazzeroni M, Uhrdin J, Carvalho S, van Elmpt W, Lambin P, Dasu A, Wersäll P, Toma-Dasu I.

Phys Med. 2018 Feb;46:45-51. doi: 10.1016/j.ejmp.2018.01.012.

PMID:
29519408
11.

The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.

Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S, Bassi F, Salgado R, Van den Eynden G, Loi S, Denkert C, Bonanni B, Viale G.

Ann Oncol. 2017 Feb 1;28(2):321-328. doi: 10.1093/annonc/mdw623.

PMID:
28426105
12.

A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Macis D, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2017 Jun;10(6):363-370. doi: 10.1158/1940-6207.CAPR-16-0298. Epub 2017 Apr 11.

13.

Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.

Lazzeroni M, Dunn BK, Pruneri G, Jereczek-Fossa BA, Orecchia R, Bonanni B, DeCensi A.

Cancer Treat Rev. 2017 Apr;55:1-9. doi: 10.1016/j.ctrv.2017.01.010. Epub 2017 Feb 11. Review.

PMID:
28262606
14.

Circulating and tissue biomarkers in early-stage non-small cell lung cancer.

Fumagalli C, Bianchi F, Raviele PR, Vacirca D, Bertalot G, Rampinelli C, Lazzeroni M, Bonanni B, Veronesi G, Fusco N, Barberis M, Guerini-Rocco E.

Ecancermedicalscience. 2017 Jan 31;11:717. doi: 10.3332/ecancer.2017.717. eCollection 2017.

15.

Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.

Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Pruneri G, Leonardi MC, Orecchia R, Galimberti V, Bonanni B, DeCensi A.

Int J Cancer. 2016 Nov 1;139(9):2127-34. doi: 10.1002/ijc.30254. Epub 2016 Jul 19.

16.

Alternate dosing schedules for cancer chemopreventive agents.

Lazzeroni M, DeCensi A.

Semin Oncol. 2016 Feb;43(1):116-122. doi: 10.1053/j.seminoncol.2015.09.014. Epub 2015 Sep 7. Review.

PMID:
26970130
17.

A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients.

Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, Pruneri G, Pagani G, Toesca A, Caldarella P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2016 May;9(5):349-56. doi: 10.1158/1940-6207.CAPR-15-0311. Epub 2016 Feb 29.

18.

A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Puccio A, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2016 Jan;9(1):89-95. doi: 10.1158/1940-6207.CAPR-15-0123. Epub 2015 Nov 2.

19.

Metformin: risk-benefit profile with a focus on cancer.

Provinciali N, Lazzeroni M, Cazzaniga M, Gorlero F, Dunn BK, DeCensi A.

Expert Opin Drug Saf. 2015 Oct;14(10):1573-85. doi: 10.1517/14740338.2015.1084289. Epub 2015 Sep 11. Review.

PMID:
26359221
20.

Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.

DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O, Petrera M, Viale G, Cuzick J, Bonanni B, Pruneri G.

Cancer Prev Res (Phila). 2015 Oct;8(10):888-94. doi: 10.1158/1940-6207.CAPR-15-0048. Epub 2015 Aug 14.

21.

Long-term effects of inhaled budesonide on screening-detected lung nodules.

Veronesi G, Lazzeroni M, Szabo E, Brown PH, DeCensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Grimaldi MC, Spaggiari L, Bonanni B.

Ann Oncol. 2015 May;26(5):1025-30. doi: 10.1093/annonc/mdv064. Epub 2015 Feb 11.

22.

Evaluating tumor response of non-small cell lung cancer patients with ¹⁸F-fludeoxyglucose positron emission tomography: potential for treatment individualization.

Toma-Dasu I, Uhrdin J, Lazzeroni M, Carvalho S, van Elmpt W, Lambin P, Dasu A.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):376-84. doi: 10.1016/j.ijrobp.2014.10.012.

PMID:
25636761
23.

Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.

Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G.

Ann Oncol. 2015 Apr;26(4):682-7. doi: 10.1093/annonc/mdv013. Epub 2015 Jan 18.

PMID:
25600567
24.

Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches.

Serrano D, Lazzeroni M, Bonanni B.

Mol Oncol. 2015 May;9(5):1008-17. doi: 10.1016/j.molonc.2014.12.006. Epub 2014 Dec 20. Review.

25.

Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence.

Toesca A, Botteri E, Lazzeroni M, Vila J, Manika A, Ballardini B, Bettarini F, Guerrieri-Gonzaga A, Bonanni B, Rotmensz N, Viale G, Veronesi P, Luini A, Veronesi U, Gentilini O.

Breast. 2014 Dec;23(6):829-35. doi: 10.1016/j.breast.2014.08.016. Epub 2014 Sep 26.

PMID:
25261930
26.

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN.

Breast Cancer Res Treat. 2014 Nov;148(1):81-90. doi: 10.1007/s10549-014-3141-1. Epub 2014 Sep 25.

27.

Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.

Gandini S, Guerrieri-Gonzaga A, Pruneri G, Serrano D, Cazzaniga M, Lazzeroni M, Veronesi P, Johansson H, Bonanni B, Viale G, Decensi A.

Ann Oncol. 2014 Mar;25(3):618-23. doi: 10.1093/annonc/mdt528. Epub 2013 Dec 18.

28.

Acceptability of chemoprevention trials in high-risk subjects.

Bonanni B, Lazzeroni M.

Ann Oncol. 2013 Nov;24 Suppl 8:viii42-viii46. doi: 10.1093/annonc/mdt328. Review.

PMID:
24131969
29.

The effect of metformin on apoptosis in a breast cancer presurgical trial.

Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell'Orto P, Lazzeroni M, Serrano D, Viale G, Bonanni B.

Br J Cancer. 2013 Nov 26;109(11):2792-7. doi: 10.1038/bjc.2013.657. Epub 2013 Oct 24.

30.

Breast cancer prevention by antihormones and other drugs: where do we stand?

Lazzeroni M, DeCensi A.

Hematol Oncol Clin North Am. 2013 Aug;27(4):657-72, vii. doi: 10.1016/j.hoc.2013.05.009. Review.

PMID:
23915737
31.

Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.

Lazzeroni M, Serrano D.

Breast Care (Basel). 2012 Aug;7(4):281-7. doi: 10.1159/000342167.

32.

A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study.

DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C, Cazzaniga M, Lazzeroni M, Rotmensz N, Santillo B, Sideri M, Cassano E, Belloni C, Muraca M, Segnan N, Masullo P, Costa A, Monti N, Vella A, Bisanti L, D'Aiuto G, Veronesi U; Italian HOT Study Group.

Ann Oncol. 2013 Nov;24(11):2753-60. doi: 10.1093/annonc/mdt244. Epub 2013 Jul 17.

PMID:
23864098
33.

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.

Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J, Lien E, Feroce I, Pruneri G, Sandri M, Bassi F, Brenelli F, Luini A, Cazzaniga M, Varricchio C, Guerrieri-Gonzaga A, DeCensi A, Bonanni B.

Breast Cancer Res. 2013 Jun 20;15(3):R47. doi: 10.1186/bcr3439.

34.

Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype.

Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, Varricchio C, Disalvatore D, Del Castillo A, Bassi F, Pagani G, DeCensi A, Viale G, Bonanni B, Pruneri G.

Br J Cancer. 2013 Apr 30;108(8):1593-601. doi: 10.1038/bjc.2013.147. Epub 2013 Apr 11.

35.

Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.

Guerrieri-Gonzaga A, Lazzeroni M, Botteri E, Serrano D, Rotmensz N, Varricchio MC, Cazzaniga M, Bollani G, Mora S, Montefrancesco C, Pruneri G, Viale G, Intra M, Galimberti V, Goldhirsch A, Bagnardi V, Bonanni B, DeCensi A.

Ann Oncol. 2013 Jul;24(7):1859-66. doi: 10.1093/annonc/mdt113. Epub 2013 Mar 26.

PMID:
23532115
36.

Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo.

Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Casadio C, Jemos C, Pizzamiglio M, Cortesi L, Radice D, Bonanni B.

BMC Cancer. 2012 Dec 5;12:575. doi: 10.1186/1471-2407-12-575.

37.

Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.

Lazzeroni M, Serrano D, Dunn BK, Heckman-Stoddard BM, Lee O, Khan S, Decensi A.

Breast Cancer Res. 2012 Oct 29;14(5):214. doi: 10.1186/bcr3233. Review.

38.

Vitamin D supplementation and cancer: review of randomized controlled trials.

Lazzeroni M, Serrano D, Pilz S, Gandini S.

Anticancer Agents Med Chem. 2013 Jan;13(1):118-25. Review.

PMID:
23094929
39.

Evaluation of nuclear reaction cross-sections and fragment yields in carbon beams using the SHIELD-HIT Monte Carlo code. Comparison with experiments.

Hultqvist M, Lazzeroni M, Botvina A, Gudowska I, Sobolevsky N, Brahme A.

Phys Med Biol. 2012 Jul 7;57(13):4369-85. doi: 10.1088/0031-9155/57/13/4369. Epub 2012 Jun 15.

PMID:
22705925
40.

Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A.

J Clin Oncol. 2012 Jul 20;30(21):2593-600. doi: 10.1200/JCO.2011.39.3769. Epub 2012 May 7.

PMID:
22564993
41.

Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.

Macis D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Magni P, Ruscica M, Lazzeroni M, Serrano D, Cazzaniga M, Mora S, Feroce I, Pizzamiglio M, Sandri MT, Gulisano M, Bonanni B, Decensi A.

J Clin Oncol. 2012 Jan 10;30(2):151-7. doi: 10.1200/JCO.2011.35.2237. Epub 2011 Dec 12.

42.

The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it.

Lazzeroni M, Gandini S, Puntoni M, Bonanni B, Gennari A, DeCensi A.

Breast. 2011 Oct;20 Suppl 3:S36-41. doi: 10.1016/S0960-9776(11)70292-2. Review.

PMID:
22015291
43.

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.

Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, Macis D, Johansson H, Pala O, Luini A, Veronesi P, Galimberti V, Dotti MC, Viale G, Bonanni B.

Cancer Prev Res (Phila). 2011 Aug;4(8):1181-9. doi: 10.1158/1940-6207.CAPR-10-0337. Epub 2011 Jun 17.

44.

Production of clinically useful positron emitter beams during carbon ion deceleration.

Lazzeroni M, Brahme A.

Phys Med Biol. 2011 Mar 21;56(6):1585-600. doi: 10.1088/0031-9155/56/6/005. Epub 2011 Feb 18.

PMID:
21335650
45.

Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules.

Veronesi G, Szabo E, Decensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Ferretti S, Pelosi G, Lazzeroni M, Serrano D, Lippman SM, Spaggiari L, Nardi-Pantoli A, Harari S, Varricchio C, Bonanni B.

Cancer Prev Res (Phila). 2011 Jan;4(1):34-42. doi: 10.1158/1940-6207.CAPR-10-0182. Epub 2010 Dec 16.

46.

Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology.

Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Varricchio MC, Veronesi G, Radice D, Feroce I, Nardi-Pantoli A, Lippman SM, Szabo E, Bonanni B.

Contemp Clin Trials. 2010 Nov;31(6):612-9. doi: 10.1016/j.cct.2010.08.006. Epub 2010 Aug 16.

47.

Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.

Haugan Moi LL, Hauglid Flågeng M, Gandini S, Guerrieri-Gonzaga A, Bonanni B, Lazzeroni M, Gjerde J, Lien EA, DeCensi A, Mellgren G.

Clin Cancer Res. 2010 Apr 1;16(7):2176-86. doi: 10.1158/1078-0432.CCR-09-1859. Epub 2010 Mar 23. Erratum in: Clin Cancer Res. 2010 Oct 15;16(20):5087. De Censi, Andrea [corrected to DeCensi, Andrea].

48.

Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.

Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H, Guerrieri-Gonzaga A, Plebani M, Basso D, Gjerde J, Mellgren G, Rotmensz N, Decensi A, Bonanni B.

Pharmacogenomics J. 2011 Apr;11(2):100-7. doi: 10.1038/tpj.2010.17. Epub 2010 Mar 23.

PMID:
20309015
49.

Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.

Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, Rotmensz N, Goldhirsch A, Varricchio C, Serrano D, Cazzaniga M, Bassi F, Luini A, Bagnardi V, Viale G, Mora S, Bollani G, Albertazzi E, Bonanni B, Decensi A.

Ann Oncol. 2010 May;21(5):949-54. doi: 10.1093/annonc/mdp408. Epub 2009 Oct 25.

PMID:
19858087
50.

Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years.

Guerrieri-Gonzaga A, Botteri E, Rotmensz N, Bassi F, Intra M, Serrano D, Renne G, Luini A, Cazzaniga M, Goldhirsch A, Colleoni M, Viale G, Ivaldi G, Bagnardi V, Lazzeroni M, Decensi A, Veronesi U, Bonanni B.

Oncologist. 2009 Mar;14(3):201-12. doi: 10.1634/theoncologist.2008-0203. Epub 2009 Mar 5.

Supplemental Content

Loading ...
Support Center